Division of Interdisciplinary Medicine and Biotechnology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
FEBS Lett. 2012 Jul 30;586(16):2389-95. doi: 10.1016/j.febslet.2012.05.052. Epub 2012 Jun 4.
We show that knockdown of 6-phosphogluconate dehydrogenase (6PGD) of the pentose phosphate pathway (PPP) inhibits growth of lung cancer cells by senescence induction. This inhibition is not due to a defect in the oxidative PPP per se. NADPH and ribose phosphate production are normal in 6PGD knockdown cells and shutdown of PPP by knockdown of glucose-6-phosphate dehydrogenase (G6PD) has little effect on cell growth. Moreover, 6PGD knockdown cells can proliferate when the PPP is bypassed by using fructose instead of glucose in medium. Significantly, G6PD knockdown rescues proliferation of cells lacking 6PGD, suggesting an accumulation of growth inhibitory glucose metabolics in cells lacking 6PGD. Therefore, 6PGD inhibition may provide a novel strategy to treat glycolyic tumors such as lung cancer.
我们表明,戊糖磷酸途径(PPP)中的 6-磷酸葡萄糖酸脱氢酶(6PGD)的敲低通过诱导衰老抑制肺癌细胞的生长。这种抑制不是由于 PPP 本身的氧化缺陷所致。NADPH 和核糖磷酸的产生在 6PGD 敲低细胞中是正常的,葡萄糖-6-磷酸脱氢酶(G6PD)的 PPP 关闭对细胞生长几乎没有影响。此外,当培养基中用果糖代替葡萄糖绕过 PPP 时,6PGD 敲低细胞可以增殖。重要的是,G6PD 敲低挽救了缺乏 6PGD 的细胞的增殖,表明缺乏 6PGD 的细胞中积累了抑制生长的葡萄糖代谢物。因此,6PGD 抑制可能为治疗肺癌等糖酵解肿瘤提供一种新策略。